We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+31.63%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.58B
AUM Growth
+$225M
Cap. Flow
+$66.3M
Cap. Flow %
4.18%
Top 10 Hldgs %
72.95%
Holding
32
New
8
Increased
10
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$74.7M
2
EPZM
Epizyme, Inc
EPZM
+$38.9M
3
OMER icon
Omeros
OMER
+$30.6M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$29.3M
5
MYGN icon
Myriad Genetics
MYGN
+$28.6M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$131M
2
LMNX
Luminex Corp
LMNX
+$55.5M
3
CORT icon
Corcept Therapeutics
CORT
+$30.6M
4
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$26M
5
PACB icon
Pacific Biosciences
PACB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CARM
26
DELISTED
Carisma Therapeutics
CARM
– –
-376,165
Closed -$10.7M
EXEL icon
27
Exelixis
EXEL
$14.3B
– –
-6,645,113
Closed -$131M
PACB icon
28
Pacific Biosciences
PACB
$404M
– –
-2,455,114
Closed -$18.2M
SPPI
29
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-2,969,027
Closed -$26M
LMNX
30
DELISTED
Luminex Corp
LMNX
– –
-2,402,787
Closed -$55.5M
STML
31
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-1,155,793
Closed -$11M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Consonance Capital Management held 32 positions worth $1.58B, up 17% from $1.36B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Consonance Capital Management deployed $66.3M of net new capital in Q1 2019, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Aerie Pharmaceuticals: 1,696,773 shares worth $80.6M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Corcept Therapeutics, an estimated $30.6M trimmed.

  • Consonance Capital Management's largest Q1 2019 buy was Aerie Pharmaceuticals: 1,696,773 shares worth $80.6M.
  • Consonance Capital Management added most to Myriad Genetics in Q1 2019, an estimated $28.6M increase.
  • Consonance Capital Management's biggest Q1 2019 reduction was Corcept Therapeutics, cutting an estimated $30.6M.
  • Consonance Capital Management fully exited Exelixis in Q1 2019, selling an estimated $131M.
  • Consonance Capital Management's ten largest holdings make up 73% of its $1.58B portfolio in Q1 2019.
  • Consonance Capital Management opened 8 new positions and closed 6 in Q1 2019.
  • Consonance Capital Management's portfolio value rose 17% quarter-over-quarter to $1.58B.

Based on Consonance Capital Management's 13F filing for Q1 2019, filed 15 May 2019.